Fluvoxamine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Obsessive-Compulsive Disorder

• Clomipramine
• Fluoxetine
• Paroxetine
• Sertraline

Other medications in Mental Health

• Gabapentin
• Guanfacine
• Haloperidol
• Iloperidone
• Imipramine
• Isocarboxazid
• Levomilnacipran
• Lisdexamfetamine

What Fluvoxamine is approved for (FDA label)

Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD) ( 1 ) . Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults ( 14.1 ) . Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1 , 14.3 ) . One maintenance study with IR fluvoxamine tablets ( 14.2 ) . 1.1 Obsessive Compulsive Disorder Fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV. Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable.

Source: Read the full FDA label on DailyMed. Label effective date: June 24, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Fluvoxamine (FDA label)

SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluvoxamine maleate extended-release capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. ( See WARNINGS AND PRECAUTIONS-Clinical Worsening and Suicide Risk [ 5.1 ] and USE IN SPECIFIC POPULATIONS-Pediatric Use [ 8.4 ] .) WARNING: SUICIDALITY and ANTIDEPRESSANTS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders ( 5.1 ) .

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fluvoxamine (FDA label)

Fluvoxamine maleate extended-release capsules are available as: 100 mg extended-release capsules: a hard gelatin capsule with blue opaque cap imprinted with “A175” in black ink and white opaque body imprinted with “100” in black ink. 150 mg extended-release capsules: a hard gelatin capsule with purple opaque cap imprinted with “A176” in black ink and white opaque body imprinted with “150” in black ink. 100 mg and 150 mg Extended-Release Capsules ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fluvoxamine (FDA label)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Most common reactions in controlled trials with OCD patients and patients from another studied population (incidence ≥5% and at least twice that for placebo) were abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating and tremor ( 6.2 ) . The following additional reactions occurred: anxiety, decreased libido, myalgia, pharyngitis, and vomiting in the OCD population; and dyspepsia, dizziness, insomnia, and yawning in another studied population.

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fluvoxamine (FDA label)

Coadministration of thioridazine, tizanidine, pimozide, alosetron, or ramelteon with fluvoxamine maleate extended-release capsules is contraindicated (see WARNINGS AND PRECAUTIONS [ 5.4 - 5.8 ] ). Coadministration of thioridazine, tizanidine, pimozide, alosetron, or ramelteon ( 4 ). Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with fluvoxamine maleate extended-release capsules or within 14 days of stopping treatment with fluvoxamine maleate extended-release capsules. Do not use fluvoxamine maleate extended-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders.

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fluvoxamine (FDA label)

Clinical Worsening/Suicide Risk: Monitor for clinical worsening of suicidal thoughts/behaviors especially during the initial months of therapy and at times of dose changes ( 5.1 ) . Bipolar Disorder: Screen for bipolar disorder ( 5.1 ) . Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including fluvoxamine maleate extended-release capsules, both when taken alone, but especially when coadministered with other serotonergic agents. If such symptoms occur, discontinue fluvoxamine maleate extended-release capsules and serotonergic agents and initiate supportive treatment. If concomitant use of fluvoxamine maleate extended-release capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.2 ) . Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants ( 5.3 ). Other Potentially Important Drug Interactions: Benzodiazepines: Use with caution.

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fluvoxamine (FDA label)

Drug Interactions (not described in Contraindications or Warnings and Precautions) include the following: Drugs Inhibiting or Metabolized by Cytochrome P450: Fluvoxamine inhibits several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP3A4, and CYP2C19) ( 7.1 ) . Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity with coadministration ( 7.2 ) . Sumatriptan: Rare postmarketing reports of weakness, hyperreflexia, and incoordination following use of an SSRI and sumatriptan. Monitor appropriately if concomitant treatment is clinically warranted ( 7.2 ) . Tacrine: Coadministration increased tacrine C max and AUC five- and eight-fold and caused nausea, vomiting, sweating, and diarrhea ( 7.2 ). Tricyclic Antidepressants (TCAs): Coadministration significantly increased plasma TCA levels.

Source: FDA prescribing information (DailyMed). Set ID: d492230c-f56a-4759-ba86-7090b9f44063. SPL document ID: 26cb8a8c-1b8a-4f72-b0c2-218b83098116. Label effective date: June 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.